Arcturus Therapeutics Holdings Inc. (ARCT): Capital Expenditures
$230.0K
Year ended 2025-12-31
$93.0K
Trailing 12 months to 2026-06-30
-69.0%
3-year compound annual growth
-33.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $230.0K | -64.5% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $648.0K | -77.7% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $2.90M | -62.5% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $7.73M | +126.8% | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | $3.41M | +95.5% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $1.74M | +113.0% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $818.0K | -44.7% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $1.48M | n/a | 2021-03-01, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.0K | -64.5% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $264.0K | -69.6% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $14.00M | +51.0% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $333.0K | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $339.0K | -39.8% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $8.30M | -0.6% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $24.81M | +535.1% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $220.0K | -29.0% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $42.77M | -45.4% |
Compare ARCT, ADCT, NRIX, ETON side by side · Screen every company in Pharmaceutical Preparations ↗